Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Learn when mutual funds can be preferable to index funds, considering objectives, risk tolerance, and horizon. Make informed allocation decisions.
25,127 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Cerebras Systems stock crashed after its latest earnings report, leaving investors asking what happened and what come...
Costco has quietly stacked cash, raising questions about shareholder returns. This guide explains the potential for a...
A rare cross‑party proposal would remove the payroll tax cap to boost funding for Social Security. If enacted, the pl...
May delinquencies rose modestly as calendar timing pushed some payments into June, but overall mortgage health remain...
Oruka stock has surged dramatically, propelled by momentum and speculation. A substantial insider sale adds another l...
El Salvador’s bitcoin reserve faces renewed IMF scrutiny as market swings test a government crypto policy, raising ac...
A surprise leadership change jolted Copart’s stock, sparking an intraday drop. This article breaks down the why, what...
A new study finds that companies investing heavily in AI per employee are expanding payrolls faster, with notable gai...
A legal fight over a listing rule has spiraled into concerns about privacy and governance inside the National Associa...
Regulatory moves around AI can move crypto markets faster than a breakthrough in code. This piece explains what happe...
A year after the OBBBA package, the impact on budgets and balance sheets is mixed. Here's a data-driven read on who g...